OMER News and Press, Omeros Corporation From 07/17/20

Without education, we are in a horrible and deadly danger of taking educated people seriously. "― G.K. Chesterton Today, we revisit a name we have covered often over the past two years. The company has been maddening for investors as the shares trade at the same level as a year ago...

Biopharma Dynavax Technologies (NASDAQ: DVAX) is one of many companies racing to develop a COVID-19 vaccine. Like many coronavirus-focused companies, Dynavax has seen its shares rise on the ongoing concern related to the pandemic -- in its case, by 50% year to date. While investors may co...

The following slide deck was published by Omeros Corporation in conjunction with this Read more ...

Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) were shared during an oral presentation at the virtual edition of the 25th Congress o...

Omeros Corporation (Nasdaq: OMER): The results of Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an oral presentation at the virtual edition of the 25th annual European Hema...

"Nothing strengthens authority so much as silence .”― Leonardo da Vinci Today, we are circling back and revisiting the investment case on Omeros ( OMER ) after this ' Tier 3 ' concern posted quarterly results on Tuesday. Like so many biotech/biopharma names, sales from ...

Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy will be presented at the 25 th Annual Congress of the European Hematology Association (EHA) to b...

Image source: The Motley Fool. Omeros   (NASDAQ: OMER) Q1 2020 Earnings Call May 11, 2020 , 4:30 p.m. ET Operator Continue reading

Omeros Corporation (OMER) Q1 2020 Earnings Conference Call May 11, 2020 4:30 PM ET Company Participants Jennifer Williams – Investor Relations Greg Demopulos – Chairman and Chief Executive Officer Mike Jacobsen – Chief Accounting Officer Conference Call Pa...

Omeros (NASDAQ: OMER ): Q1 Non-GAAP EPS of -$0.41 misses by $0.07 ; GAAP EPS of -$0.53 misses by $0.19 . Revenue of $23.5M (+7.9% Y/Y) misses by $6.71M . Press Release More news on: Omeros Corporation, Earnings news and commentary, Healthcare stocks news,